Emmanuel Seront1,2, Sylvie Rottey3, Bertrand Filleul2, Philippe Glorieux4, Jean-Charles Goeminne5, Vincent Verschaeve6, Jean-Marie Vandenbulcke7, Brieuc Sautois8, Petra Boegner9, Aline Gillain1, Aline van Maanen10, Jean-Pascal Machiels1. 1. Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. 2. Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium. 3. Department of Medical Oncology, Ghent University Hospital and Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium. 4. Department of Medical Oncology, Cliniques du Sud-Luxembourg-Vivalia, Arlon, Belgium. 5. Department of Medical Oncology, Centre de Maternité Sainte Elisabeth, Namur, Belgium. 6. Department of Medical Oncology, Grand Hopital de Charleroi, Charleroi, Belgium. 7. Department of Medical Oncology, Réseau Hospitalier de Médecine Sociale, Tournai, Belgium. 8. Department of Medical Oncology, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium. 9. Department of Medical Oncology, Centre Hospitalier Epicura, Baudour, Belgium. 10. Statistical Support Unit, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Abstract
OBJECTIVE: To assess, in a multicentre phase II trial, the safety and efficacy of BEZ235, an oral pan-class I phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) complex1/2 inhibitor, in locally advanced or metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy. PATIENTS AND METHODS: Patients with locally advanced or metastatic TCC progressing after platinum therapy were prospectively stratified by PI3K/Akt/mTOR pathway alterations, defined as PTEN loss and PIK3CA mutation. All patients received BEZ235 until progressive disease or unacceptable toxicity. The primary endpoint was the progression-free survival (PFS) rate at 16 weeks. This study was, however, closed prematurely because BEZ235 was withdrawn from further development. RESULTS: A total of 20 patients (18 without and two with PI3K/Akt/mTOR alterations) were enrolled and received BEZ235. One partial response (5%) and two cases of stable disease (10%) were observed, all in patients without PI3K/mTOR pathway alterations. The PFS rate at 8 and 16 weeks was 15 and 10%, respectively; the median (range) PFS was 62 (38-588) days (95% confidence interval [CI] 53-110); and the median (range) overall survival was 127 (41-734) days (95% CI 58-309). Among the 90% of patients who experienced drug-related adverse events of any grade, 50% experienced grade 3-4 adverse events, including stomatitis (15%), fatigue (5%), nausea (5%), diarrhoea (5%), renal failure (5%), cutaneous rash (5%), hepatotoxicity (5%) and hypertension (5%). CONCLUSION: BEZ235 showed modest clinical activity and an unfavourable toxicity profile in patients with advanced and pretreated TCC; however, a minority of patients experienced a clinical benefit, suggesting that a complete blockade of the PI3K/mTOR axis could improve outcome in some specific patients. Furthermore, this study showed that molecular stratification of patients for personalized medicine before treatment is feasible.
OBJECTIVE: To assess, in a multicentre phase II trial, the safety and efficacy of BEZ235, an oral pan-class I phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) complex1/2 inhibitor, in locally advanced or metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy. PATIENTS AND METHODS: Patients with locally advanced or metastatic TCC progressing after platinum therapy were prospectively stratified by PI3K/Akt/mTOR pathway alterations, defined as PTEN loss and PIK3CA mutation. All patients received BEZ235 until progressive disease or unacceptable toxicity. The primary endpoint was the progression-free survival (PFS) rate at 16 weeks. This study was, however, closed prematurely because BEZ235 was withdrawn from further development. RESULTS: A total of 20 patients (18 without and two with PI3K/Akt/mTOR alterations) were enrolled and received BEZ235. One partial response (5%) and two cases of stable disease (10%) were observed, all in patients without PI3K/mTOR pathway alterations. The PFS rate at 8 and 16 weeks was 15 and 10%, respectively; the median (range) PFS was 62 (38-588) days (95% confidence interval [CI] 53-110); and the median (range) overall survival was 127 (41-734) days (95% CI 58-309). Among the 90% of patients who experienced drug-related adverse events of any grade, 50% experienced grade 3-4 adverse events, including stomatitis (15%), fatigue (5%), nausea (5%), diarrhoea (5%), renal failure (5%), cutaneous rash (5%), hepatotoxicity (5%) and hypertension (5%). CONCLUSION:BEZ235 showed modest clinical activity and an unfavourable toxicity profile in patients with advanced and pretreated TCC; however, a minority of patients experienced a clinical benefit, suggesting that a complete blockade of the PI3K/mTOR axis could improve outcome in some specific patients. Furthermore, this study showed that molecular stratification of patients for personalized medicine before treatment is feasible.
Authors: Grant R Campbell; Rachel S Bruckman; Shayna D Herns; Shweta Joshi; Donald L Durden; Stephen A Spector Journal: J Biol Chem Date: 2018-02-23 Impact factor: 5.157
Authors: Pei Shi Ong; Louis Z Wang; Xiaoyun Dai; Sheng Hsuan Tseng; Shang Jun Loo; Gautam Sethi Journal: Front Pharmacol Date: 2016-10-25 Impact factor: 5.810
Authors: Anuja Sathe; Géraldine Chalaud; Immanuel Oppolzer; Kit Yeng Wong; Margarita von Busch; Sebastian C Schmid; Zhichao Tong; Margitta Retz; Juergen E Gschwend; Wolfgang A Schulz; Roman Nawroth Journal: PLoS One Date: 2018-01-22 Impact factor: 3.240
Authors: Trisha M Wise-Draper; Ganesh Moorthy; Mohamad A Salkeni; Nagla Abdel Karim; Hala Elnakat Thomas; Carol A Mercer; M Shalaan Beg; Sue O'Gara; Olugbenga Olowokure; Hassana Fathallah; Sara C Kozma; George Thomas; Olivier Rixe; Pankaj Desai; John C Morris Journal: Target Oncol Date: 2017-06 Impact factor: 4.493
Authors: Victor McPherson; Brendan Reardon; Aravind Bhayankara; Sasinya N Scott; Mariel E Boyd; Ilana R Garcia-Grossman; Ashley M Regazzi; Asia S McCoy; Philip H Kim; Hikmat Al-Ahmadie; Irina Ostrovnaya; Andrew J Roth; Azeez Farooki; Michael F Berger; Jonathan E Rosenberg; David B Solit; Eliezer Van Allen; Matthew I Milowsky; Dean F Bajorin; Gopa Iyer Journal: Cancer Date: 2020-08-07 Impact factor: 6.921
Authors: Maria I Carlo; Ana M Molina; Yulia Lakhman; Sujata Patil; Kaitlin Woo; John DeLuca; Chung-Han Lee; James J Hsieh; Darren R Feldman; Robert J Motzer; Martin H Voss Journal: Oncologist Date: 2016-06-10